June 12, 2020
In this week’s episode of DeviceTalks Weekly, Tom Salemi, editorial director of DeviceTalks events and content, visits with Renee Ryan, the CEO of neuromodulation startup Cala Health.
Ryan came to Cala from the venerable medtech investor Johnson & Johnson Development Corp., where she made over 15 investments helping to create companies including Auris Surgical, Cala and digital surgery play Verb Surgical, J&J’s joint venture with Verily. “I really set my mind to [asking] was there a way we could create our own opportunities,” she said of her eight years as the corporate investor.
We ask Ryan about her move into medtech investing from investment banking as well as the “secret power” that helped her succeed as an investor and an executive.
We’ll also discuss the unique commercial strategy Cala is employing as it begins rolling out its Cala Trio, a bioelectronic device developed to treat essential tremor.
Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.